Sun Pharmaceutical Stock Screener | Share Price & Fundamental Analysis
SUNPHARMA
Pharmaceuticals
Share Price NSE
₹1714.60
▼
-3.40 (-0.20%)
Share Price BSE
₹1713.60
▼
-4.90 (-0.29%)
Track Sun Pharmaceutical share price live with TickJournal's free stock screener.
Analyze Sun Pharmaceutical share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Sun Pharmaceutical Market Cap
₹406,351.37 Cr.
SUNPHARMA P/E Ratio (TTM)
37.86
Sun Pharmaceutical P/B Ratio
5.33
EPS (TTM)
₹45.60
Dividend Yield
0.93%
Debt to Equity
0.04
SUNPHARMA 52 Week High
₹1841.60
Sun Pharmaceutical 52 Week Low
₹1562.80
Operating Margin
28.00%
Profit Margin
21.07%
SUNPHARMA Revenue (TTM)
₹16,048.00
EBITDA
₹4,986.00
Net Income
₹3,381.00
Total Assets
₹92,101.00
Total Equity
₹72,486.00
Sun Pharmaceutical Share Price History - Stock Screener Chart
Screen SUNPHARMA historical share price movements with interactive charts. Analyze price trends and patterns.
Sun Pharmaceutical Company Profile - Fundamental Screener
Screen Sun Pharmaceutical company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for SUNPHARMA shares.
Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company based in India. It manufactures and markets a wide range of pharmaceutical formulations including generics, branded generics, complex products, over-the-counter drugs, and active pharmaceutical ingredients. The company has a diverse portfolio covering multiple therapeutic areas and dosage forms. Sun...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Dilip S Shanghvi
ISIN
INE044A01036
Website
https://www.sunpharma.com
Sun Pharmaceutical Balance Sheet Screener
Screen SUNPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 92,101 | 85,500 | 80,744 | 69,808 | 67,667 | 68,253 | 64,694 | 64,516 | 61,410 | 55,530 |
| Current Assets | 52,594 | 43,433 | 39,862 | 34,865 | 30,442 | 31,654 | 31,069 | 31,636 | 32,954 | 29,941 |
| Fixed Assets | 22,586 | 23,248 | 24,065 | 22,665 | 21,553 | 22,847 | 21,837 | 18,853 | 17,675 | 15,872 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1,420 | 1,390 | 1,522 | 1,533 | 2,041 | 3,421 | 2,632 | 2,454 | 3,093 | 5,319 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 72,486 | 67,126 | 59,316 | 51,066 | 49,480 | 49,125 | 44,723 | 42,198 | 40,431 | 37,068 |
| Share Capital | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 241 |
| Reserves & Surplus | 71,978 | 63,427 | 55,755 | 47,771 | 46,223 | 45,025 | 41,169 | 38,074 | 36,400 | 32,741 |
Sun Pharmaceutical Income Statement Screener - Profit & Revenue Analysis
Screen Sun Pharmaceutical income statement and profit fundamentals.
Analyze SUNPHARMA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Sun Pharmaceutical share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16,048 | 14,875 | 14,251 | 13,429 | 13,903 | 13,618 | 13,057 | 12,419 | 12,407 | 12,297 | 11,990 | 11,099 | 11,274 | 10,894 | 10,646 |
| Expenses | 11,062 | 9,951 | 10,368 | 9,604 | 9,983 | 9,352 | 9,045 | 9,049 | 8,974 | 9,013 | 8,932 | 8,300 | 8,237 | 7,996 | 7,877 |
| EBITDA | 4,986 | 4,924 | 3,883 | 3,824 | 3,920 | 4,266 | 4,012 | 3,370 | 3,433 | 3,284 | 3,058 | 2,799 | 3,037 | 2,899 | 2,769 |
| Operating Profit % | 28.00% | 31.00% | 25.00% | 25.00% | 26.00% | 29.00% | 28.00% | 23.00% | 26.00% | 25.00% | 24.00% | 23.00% | 26.00% | 26.00% | 26.00% |
| Depreciation | 732 | 730 | 701 | 664 | 631 | 626 | 655 | 650 | 622 | 633 | 651 | 672 | 660 | 610 | 588 |
| Interest | 78 | 100 | 75 | 49 | 52 | 69 | 62 | 74 | 35 | 49 | 81 | 93 | 46 | 19 | 14 |
| Profit Before Tax | 4,227 | 4,168 | 3,173 | 3,254 | 3,476 | 3,598 | 3,424 | 2,816 | 3,000 | 2,791 | 2,481 | 2,240 | 2,472 | 2,412 | 2,285 |
| Tax | 846 | 1,043 | 880 | 1,100 | 563 | 561 | 563 | 157 | 440 | 406 | 476 | 257 | 291 | 157 | 191 |
| Net Profit | 3,381 | 3,125 | 2,293 | 2,154 | 2,913 | 3,037 | 2,861 | 2,659 | 2,561 | 2,385 | 2,006 | 1,983 | 2,181 | 2,256 | 2,093 |
| EPS | 14.00 | 13.00 | 9.50 | 9.00 | 12.10 | 12.70 | 11.80 | 11.10 | 10.50 | 9.90 | 8.40 | 8.30 | 9.00 | 9.40 | 8.60 |
Sun Pharmaceutical Cash Flow Screener - Liquidity Fundamentals
Screen SUNPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 14,072 | 12,135 | 4,959 | 8,985 | 6,170 | 6,555 | 2,196 | 3,907 | 7,082 | 6,686 |
| Investing Activities | -5,183 | -763 | -7,220 | -5,556 | 407 | -2,225 | -310 | -3,104 | -4,186 | -3,949 |
| Financing Activities | -7,906 | -6,710 | 2,376 | -5,194 | -5,981 | -5,715 | -2,731 | -1,539 | -2,285 | -1,889 |
| Net Cash Flow | 983 | 4,662 | 116 | -1,765 | 596 | -1,386 | -844 | -736 | 611 | 848 |
Sun Pharmaceutical Shareholding Pattern Screener
See Sun Pharmaceutical shareholding pattern with promoter, FII, and DII holdings.
Check Sun Pharmaceutical promoter holding and ownership changes for SUNPHARMA on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% |
| FII Holding | 17.96% | 17.26% | 16.55% | 16.12% | 17.72% | 17.23% | 18.02% | 18.05% |
| DII Holding | 18.70% | 19.50% | 20.24% | 20.82% | 18.83% | 19.28% | 18.61% | 18.55% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 5.42% | 5.35% | 5.53% | 5.40% | 5.44% | 5.57% | 5.43% | 5.47% |
| Other Holding | 3.45% | 3.42% | 3.20% | 3.18% | 3.53% | 3.44% | 3.46% | 3.46% |
| Shareholder Count | 704,983 | 723,770 | 743,877 | 710,900 | 631,392 | 673,217 | 657,317 | 689,623 |
Sun Pharmaceutical Share Dividend Screener - Share Yield Analysis
Check Sun Pharmaceutical dividend history with payout and yield data.
View Sun Pharmaceutical dividend details including ex-dates and amounts for SUNPHARMA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹16.00 | 0.91% |
| 2024-March | ₹13.50 | 0.78% |
| 2023-March | ₹11.50 | 0.71% |
| 2022-March | ₹10.00 | 1.01% |
| 2021-March | ₹7.50 | 0.82% |
| 2020-March | ₹4.00 | 0.67% |
| 2019-March | ₹2.75 | 0.78% |
| 2018-March | ₹2.00 | 0.42% |
| 2017-March | ₹3.50 | 0.71% |
Sun Pharmaceutical Stock Index Membership
See which indices include Sun Pharmaceutical stock.
Check SUNPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE100
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX BSEDSI
BSE INDEX BSELVI
BSE INDEX BSEMOI
BSE INDEX DOL100
BSE INDEX DOL30
BSE INDEX ESG100
BSE INDEX LCTMCI
BSE INDEX LMI250
BSE INDEX LRGCAP
BSE INDEX MFG
BSE INDEX SNSX50
BSE SENSEX SIXTY
BSE SENSEX SIXTY 65:35
GIFT NIFTY
INDIA VIX
NIFTY 100
NIFTY 200
NIFTY 50
NIFTY 500
NIFTY ALPHA QUALITY LOW-VOLATILITY 30
NIFTY ALPHA QUALITY VALUE LOW VOLATILITY 30
NIFTY ALPHALOWVOL
NIFTY GROWSECT 15
NIFTY HEALTHCARE
NIFTY INDIA MFG
NIFTY LARGEMID250
NIFTY LOW VOLATILITY 50
NIFTY MULTI MFG
NIFTY PHARMA
NIFTY QUALITY LOW VOLATILITY 30
NIFTY TOP 20 EQUAL WEIGHT
NIFTY TOTAL MKT
NIFTY100 ENHANCED ESG
NIFTY100 EQL WGT
NIFTY100 ESG
NIFTY100 LOWVOL30
NIFTY200MOMENTM30
NIFTY50 EQL WGT
NIFTY50 SHARIAH
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 SHARIAH
SENSEX
Sun Pharmaceutical Market Events Screener - Corporate Actions
Get Sun Pharmaceutical corporate actions including splits, bonuses, and buybacks.
Check Sun Pharmaceutical stock events that may affect SUNPHARMA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-02-05 | 2026-02-05 | Dividend | ₹ 11.00 /share | 6.83% |
| 2026-01-31 | 2026-01-31 | Quarterly Result Announcement | NA | -4.69% |
| 2025-11-05 | 2025-11-05 | Quarterly Result Announcement | NA | 1.29% |
| 2025-07-31 | 2025-07-31 | Annual General Meeting | NA | 0.19% |
| 2025-07-31 | 2025-07-31 | Quarterly Result Announcement | NA | 4.32% |
| 2025-07-07 | 2025-07-07 | Dividend | ₹ 5.50 /share | -3.17% |
| 2025-05-22 | 2025-05-22 | Quarterly Result Announcement | NA | -0.76% |
| 2025-02-06 | 2025-02-06 | Dividend | ₹ 10.50 /share | 0.82% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -1.01% |
| 2025-01-21 | 2025-01-21 | Extraordinary General Meeting | NA | -1.55% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -2.94% |
| 2024-08-05 | 2024-08-05 | Annual General Meeting | NA | 13.88% |
| 2024-07-12 | 2024-07-12 | Dividend | ₹ 5.00 /share | 2.73% |
| 2024-02-09 | 2024-02-09 | Dividend | ₹ 8.50 /share | 9.38% |
| 2023-07-28 | 2023-07-28 | Dividend | ₹ 4.00 /share | 20.10% |
Sun Pharmaceutical Competitors Screener - Peer Comparison
Screen SUNPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 406,351 | 37.86 | 54,729 | 9.71% | 10,980 | 37.98 |
| Divis Laboratories | 155,472 | 63.26 | 9,712 | 18.67% | 2,191 | 33.24 |
| Torrent Pharmaceuticals | 134,945 | 61.20 | 11,539 | 6.99% | 1,911 | 32.75 |
| Lupin | 103,954 | 22.26 | 22,910 | 13.74% | 3,306 | 47.35 |
| Dr Reddys Laboratories | 101,601 | 18.27 | 33,741 | 16.73% | 5,725 | 39.36 |
| Cipla | 96,320 | 21.31 | 28,410 | 7.12% | 5,291 | 26.86 |
| Zydus Life Science | 86,964 | 17.29 | 23,511 | 18.55% | 4,615 | 41.42 |
| Mankind Pharma | 82,499 | 45.81 | 12,744 | 20.90% | 2,007 | 41.40 |
| Aurobindo Pharma | 77,462 | 22.37 | 32,346 | 9.43% | 3,484 | 64.38 |
| Alkem Laboratories | 62,867 | 25.87 | 13,458 | 3.70% | 2,216 | 42.54 |
Sun Pharmaceutical Company Announcements - News Screener
Screen SUNPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-08 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-03-31 | Updates On Fibromun And Nidlegy | - |
| 2026-03-31 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-03-21 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-03-17 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-03-17 | Shareholder Satisfaction Survey On RTA Services | - |
| 2026-03-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-24 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-02-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-02 | Sustainability Report For The Financial Year 2024-25 | - |
| 2026-02-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-01-31 | Q3FY26 Earnings Call Audio Recording | - |
| 2026-01-31 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-01-31 | Corporate Action-Board approves Dividend | - |
| 2026-01-31 | Unaudited Financial Results For The Quarter And Nine Months Ended 31 December 2025 | - |
| 2026-01-23 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |